Integrated assessment of potential value of erbB-2 amplification or expression status as novel therapy target in Chinese children and adolescents with osteosarcoma.
- Author:
Jian SHANG
1
;
Zheng-gang BI
;
Hong-fei JI
;
Wen-bo WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Bone Neoplasms; genetics; therapy; Child; Dimerization; Female; Gene Amplification; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Male; Osteosarcoma; genetics; therapy; Receptor, ErbB-2; analysis; antagonists & inhibitors; Reverse Transcriptase Polymerase Chain Reaction
- From: Chinese Medical Journal 2009;122(13):1521-1524
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDTargeted tumor therapies have been making rapid progress in recent years, and the erbB-2 oncogene is a suitable target. There was much discussion about the level of erbB-2 in osteosarcoma. The aim of this study was to investigate the erbB-2 amplification or expression status in osteosarcoma.
METHODSFluorescence in situ hybridization (FISH) and DNA probes for erbB-2 and centromere 17 were used to examine the erbB-2 gene amplification status in 32 osteosarcoma samples, and expression of erbB-2 was analyzed by immunohistochemistry (IHC) and reverse transcription-polymerase chain reaction (RT-PCR).
RESULTSNone of the 32 osteosarcomas was observed by FISH to have the erbB-2 gene amplified, and no distinguishable membrane staining was seen in any case yet, nevertheless, erbB-2 overexpression was present in 6 tumor samples by RT-PCR.
CONCLUSIONSThe status of erbB-2 gene amplification and membrane overexpression is rare in osteosarcomas, and might suggest that the erbB-2 target agent should not be applied to osteosarcomas as single treatment.
